MIR149 (MicroRNA 149)

Phytochemicals derived from Pithecellobium dulce, particularly oleanolic acid and rutin, emerge as promising selective modulators of AKT1 and AKT2, respectively. These findings provide a mechanistic and structural foundation for the development of isoform-guided AKT-targeted therapies and support further experimental validation toward precision oncology applications.

These findings highlight the potential of GDEVs as an anti-inflammatory therapy for RA. Given their stability and bioavailability, the oral administration of GDEVs could be a promising non-invasive treatment for future clinical applications.

In PMLs, basal cells with high levels of NLRC5 were in close spatial proximity to CD8+ T cells, suggesting that these cells exhibit increased functional MHC-I gene expression in vivo. These findings indicate a functional role for hsa-miR-149-5p in PML progression/persistence and suggest this axis as a potential therapeutic target for PML immunomodulation.

Collectively, these findings establish a mechanistic axis in which miR-149-3p-mediated suppression of TIMP3 promotes sorafenib resistance, EMT, and stemness in HCC. This work identifies TIMP3 as a pivotal determinant of tumor aggressiveness and suggests restoring TIMP3 or targeting downstream pathways as strategies to overcome resistance.

[This retracts the article on p. 2209 in vol. 7, PMID: 29218245.].

Drug sensitivity analysis showed that the risk score was significantly correlated with the sensitivity to various chemotherapeutic drugs (e.g., Methotrexate, Paclitaxel). This study established a reliable prognostic risk scoring model for HCC by screening differentially expressed glycolysis-related miRNAs, which effectively distinguishes between high-risk and low-risk patients and predicts patient survival. Additionally, the model is closely associated with the immune microenvironment and drug sensitivity, offering strong support for personalized treatment and clinical decision-making in HCC.

This preliminary study demonstrated that miR-107, miR-134-5p, miR-149-5p, and miR-370-3p were significantly overexpressed in PCa patients compared to the BPH group. ROC analysis highlighted their diagnostic potential in distinguishing BPH from PCa. Despite the limited sample size, these findings provide early evidence to guide future research on the diagnostic value of miRNAs in prostate cancer.

BID, specifically the BID-EL isoform, serves as a prognostic and diagnostic biomarker in COAD, highlighting the need for further research on its potential as a therapeutic target in this disease.

Circ_0075829 seems to play an oncogenic role in H. pylori-associated gastric malignancies and may serve as a promising indicator for predicting outcomes in gastric cancer, which underpins a more theoretical basis for the progression of new therapeutic approaches to treating gastric cancer.

Overall, our investigation elucidates the temporal dynamic changes in host miRNAs and their potential target genes at the early, middle and late stages of E. multilocularis infection, which allows us to understand the roles of miRNAs in host-parasite interactions throughout infection and provides a reference for further studies of molecular pathogenesis and new drug or vaccine targets for control of AE.

The synergistic effects of oleuropein and azacitidine suggest a promising therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are warranted to validate these findings and optimize treatment protocols.